



with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed within three months of the filing date of this application.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Dated: November 7, 2003

Respectfully submitted,



Jay P. Lessler  
Registration No. 41,151  
Attorney for Applicant(s)

DARBY & DARBY  
Post Office Box 5257  
New York, NY 10150-5257  
(212) 527-7700



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,143
				Filing Date	Concurrently Herewith
				First Named Inventor	Connie Sanchez
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05432/100J951-US4

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-6,469,064 B2	10-22-2002	Druzgala	
	AB	US-6,333,357 B1	12-25-2001	Eig	
	AC	US-6,159,971	12-12-2000	Berg et al.	
	AD	US-6,147,072	11-14-2000	Bymaster et al.	
	AE	US-6,069,177	05-30-2000	Carlier et al.	
	AF	US-5,962,514	10-05-1999	Evenden et al.	
	AG	US-5,958,429	09-28-1999	Wong	
	AH	US-5,788,986	08-04-1998	Dodman	
	AI	US-5,648,396	07-15-1997	Young et al.	
	AJ	US-5,296,507	03-22-1994	Tanaka et al.	
	AK	US-5,114,976	05-19-1992	Norden	
	AL	US-4,962,128	10-09-1990	Doogen et al.	
	AM	US-4,943,590	07-24-1990	Boegesoe et al.	
	AN	US-4,902,710	02-20-1990	Foster et al.	
	AO	US-4,650,884	01-23-1979	Bogeso et al.	
	AP	US-4,136,193	01-23-1979	Bogeso et al.	
	AQ	US-3,467,675	09-16-1969	Peterson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-00/15220	03-23-2000	Astra Aktiebolag		
	BB	WO-01/54681 A2	08-02-2001	Massachusetts Institute of Technology		
	BC	WO-00/15219	03-23-2000	Astra Aktiebolag		
	BD	WO-00/03701	01-27-2000	Massachusetts Institute of Technology		
	BE	WO-00/02551	01-20-2000	NPS Pharmaceutical, Inc.		
	BF	EP-0759299	02-26-1997	Eli Lilly and Company		
	BG	EP-0714663 A2	06-05-1996	Eli Lilly and Company		
	BH	WO-93/09769	05-27-1993	Sepracor, Inc.		
	BI	WO-00/34263	06-15-2000	H Lundbeck A/S		
	BJ	WO-92/18005	10-29-1992	National Institutes of Health		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

{W:054 321001	Date Considered
------------------	--------------------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,143
				Filing Date	Concurrently Herewith
				First Named Inventor	Connie Sanchez
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05432/100J951-US4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	A.F. Joubert et al., "Citalopram and Anxiety Disorders," Rev. Contemp. Pharmacother 10: 79-131 (1999)	
	CB	Ulla M. Lepola et al., "A Controlled Perspective, 1 -Year Trial of Citalopram in the Treatment of Panic Disorder," J. Clin. Psychiatry 59, 10: 528-534 (1998)	
	CC	H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," Acta Psychiatrica Scandinavica 96:343-346 (1997)	
	CD	Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," Journal of Serotonin Research 1: 29-33 (1996)	
	CE	Bigler, Allan et al., "Quantitative Structure-activity Relationships in a Series of Selective 5-HT uptake inhibitors," Eur. J. Med. Chem. 3:289-295 (1997)	
	CF	Soraya Seedat et al., "Open Trial of Citalopram in adults with post-traumatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000)	
	CG	Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383:223-229 (1999)	
	CH	Jennifer Y. Tan et al., "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999)	
	CI	Mario Amore et al., "Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Fluoxetine vs. Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999)	
	CJ	Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997)	
	CK	Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7:241-242 (1997)	
	CL	Takeshi Inoue et al., "Effect of italoqram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996)	
	CM	U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996)	
	CN	J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995)	
	CO	American Psychiatric Associations, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

{W:054 3211001	Date Considered
-------------------	--------------------